Alterity Therapeutics Ltd has released a press release.
First Regulatory Authorization to Proceed with Phase 2 Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- ATH Annual General Meeting Presentation
- Chairmans Address 2021 Annual General Meeting
- New Data Advance ATH434 as Neurodegeneration treatment
- Expanded ATH434 Phase 2 Clinical Development Program
- Form 20-F
Later from Alterity Therapeutics
- New US Patent for Compounds to Treat Neurodegeneration
- Response to ASX Query
- New publication shows ATH434 rescues neurons in MSA model
- UK Regulatory Authorisation to Proceed with Phase 2 Trial
- Alterity Launches ATH434 Phase 2 Clinical Trial
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics